Literature DB >> 24729388

The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience.

Eleftherios P Mamounas1, Gong Tang, Qing Liu.   

Abstract

Adjuvant systemic therapy significantly reduces rates of distant recurrence and death. The effect of systemic therapy is not limited to reducing distant recurrences but also extends to reducing loco-regional recurrences, and rates of loco-regional recurrence have steadily declined over the past 25 years. This review focuses on the effect of adjuvant systemic therapy on rates of ipsilateral breast tumor recurrence following lumpectomy plus breast irradiation in several pivotal NSABP trials in early-stage breast cancer.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant systemic therapy; ipsilateral breast tumor recurrence; lumpectomy

Mesh：

Year:  2014        PMID： 24729388      PMCID： PMC5604791          DOI： 10.1002/jso.23609

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  35 in total

1.  Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

Authors:  A Wallgren; M Bonetti; R D Gelber; A Goldhirsch; M Castiglione-Gertsch; S B Holmberg; J Lindtner; B Thürlimann; M Fey; I D Werner; J F Forbes; K Price; A S Coates; J Collins
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

2.  Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.

Authors:  B Fisher; C Redmond
Journal:  J Natl Cancer Inst Monogr       Date:  1992

3.  HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

Authors:  S Paik; J Bryant; E Tan-Chiu; G Yothers; C Park; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

4.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

5.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Authors:  Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2011-03-11       Impact factor: 13.506

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Authors:  S Paik; J Bryant; C Park; B Fisher; E Tan-Chiu; D Hyams; E R Fisher; M E Lippman; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

9.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Authors:  A D Thor; D A Berry; D R Budman; H B Muss; T Kute; I C Henderson; M Barcos; C Cirrincione; S Edgerton; C Allred; L Norton; E T Liu
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

10.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

Authors:  B Fisher; C Redmond; N V Dimitrov; D Bowman; S Legault-Poisson; D L Wickerham; N Wolmark; E R Fisher; R Margolese; C Sutherland
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245
View more
  8 in total

1.  Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Peter M Ravdin; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2019-06-03       Impact factor: 91.245

2.  Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.

Authors:  Irene L Wapnir; Shari Gelber; Stewart J Anderson; Eleftherios P Mamounas; André Robidoux; Miguel Martín; Johan W R Nortier; Charles E Geyer; Alexander H G Paterson; István Láng; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Meredith M Regan; Norman Wolmark; Stefan Aebi
Journal:  Ann Surg Oncol       Date:  2016-09-23       Impact factor: 5.344

3.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

4.  Comparison of Oncoplastic Breast-Conserving Therapy and Standard Breast-Conserving Therapy in Early-Stage Breast Cancer Patients.

Authors:  Yuan Zhou; Yixiao Liu; Yu Wang; Yanfei Wu
Journal:  Med Sci Monit       Date:  2021-01-01

5.  Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer.

Authors:  Fang Chen; Timothy S K Hui; Lingyu Ma; Yaqing Nong; Ying Han; Haiman Jing; Eric K W Lee; Zhiyuan Xu; Pingfu Fu; Amy Tien Yee Chang; Victor Hsue; Feng-Ming Spring Kong
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

6.  Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.

Authors:  Corinne Renier; John Do; Andrea Reyna-Neyra; Deshka Foster; Abhijit De; Hannes Vogel; Stefanie S Jeffrey; Victor Tse; Nancy Carrasco; Irene Wapnir
Journal:  Oncotarget       Date:  2016-08-23

7.  Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.

Authors:  Stina Garvin; Husam Oda; Lars-Gunnar Arnesson; Annelie Lindström; Ivan Shabo
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-03       Impact factor: 4.553

8.  Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23.

Authors:  Kyubo Kim; Hae Jin Park; Kyung Hwan Shin; Jin Ho Kim; Doo Ho Choi; Won Park; Seung Do Ahn; Su Ssan Kim; Dae Yong Kim; Tae Hyun Kim; Jin Hee Kim; Jiyoung Kim
Journal:  Cancer Res Treat       Date:  2018-01-08       Impact factor: 4.679
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.